Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

David Planchard, Benjamin Besse, Harry Groen, Sayed Hashemi, Julien Mazieres, Tae Min Kim, Elisabeth A. Quoix, Pierre Jean Souquet, Fabrice Barlesi, Christina S. Baik, Liza C. Villaruz, Ronan Joseph Kelly, Shirong Zhang, Monique Tan, Eduard Gasal, Libero Santarpia, Bruce E. Johnson

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of Clinical Oncology
Volume38
Issue number15
Publication statusPublished - 20 May 2020

Cite this